Abstract: The present disclosure relates, in general, to methods for generating engineered antigen-specific T cell receptors, cells and non-human animals comprising such engineered T cell receptors and methods of making engineered T cell receptors. The engineered T cell receptors can be specific for cancer or immunology targets, such as mesothelin, and are useful in developing therapies for cancer, autoimmune diseases, infectious diseases and other conditions or disorders.

Abstract: The present disclosure relates, in general, to a genetically engineered T cell comprising a modified genome expressing a protein of interest, and use thereof in cell therapy.

Abstract: Induced pluripotent stem cells (iPSCs) derived from a T cell of a T cell subset. T cells derived from iPSCs derived from a T cell. Methods of deriving iPSCs from a T cell. Methods of deriving T cells from iPSCs including deriving a T cell of a T cell subset from an iPSC. Methods of engineering chimeric antigen receptor (CAR)-expressing or T cell receptor (TCR)-expressing iPSC. Methods of administering T cells derived using the methods disclosed. Induced pluripotent stem cell lines derived from T cells, methods of deriving induced pluripotent stem cell lines, and methods of deriving T cells from induced pluripotent stem cell lines.

Abstract: The present disclosure relates, in general, to non-viral methods for generating engineered B cell, and use of such B cells as cell-based therapeutics to treat disease.

Abstract: Disclosed herein are methods of stimulating and expanding polyclonal gamma delta T cells (GDTCs) in vitro. More specifically, anti-gamma delta T cell receptor (GDTCR) antibody is used in combination with anti-CD28 antibody and one or more of IL-2, IL-7, and IL-15 to efficiently expand GDTCs in vitro.

Abstract: The present invention provides efficient methods for producing genetically modified natural killer (NK) cells using a base editor and guide RNA(s). Genetically modified NK cells produced by these methods and the use of these cells in the treatment of cancer are also provided.

Abstract: The present invention provides genomic engineering methods that utilize base editors to perform targeted gene knockins and gene knockouts with high efficiency. Cells that have been genetically modified according to these methods are also provided, as are methods of using the modified cells in a treatment for cancer.

Abstract: Provided herein are methods, compositions, and kits for expanding natural killer cells in the absence of feeder cells.

Abstract: Methods of gene correction, methods of generating induced pluripotent stem cells (iPSCs), and methods of deriving multi-lineage cell types with therapeutic value. In some embodiments, the gene correction affects the expression and/or function of the functional type VII collagen protein (C7).

Abstract: Induced pluripotent stem cells (iPSCs) derived from a T cell of a T cell subset. T cells derived from iPSCs derived from a T cell. Methods of deriving iPSCs from a T cell. Methods of deriving T cells from iPSCs including deriving a T cell of a T cell subset from an iPSC. Methods of engineering chimeric antigen receptor (CAR)-expressing or T cell receptor (TCR)-expressing iPSC. Methods of administering T cells derived using the methods disclosed. Induced pluripotent stem cell lines derived from T cells, methods of deriving induced pluripotent stem cell lines, and methods of deriving T cells from induced pluripotent stem cell lines.

Abstract: Methods of gene correction, methods of generating induced pluripotent stem cells (iPSCs), and methods of deriving multi-lineage cell types with therapeutic value. In some embodiments, the gene correction affects the expression and/or function of the functional type VII collagen protein (C7).